Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 1997

View Archived Issues

DuPont Merck receives FDA approval for nuclear imaging breast cancer test

Positive efficacy profile reported for Zonagen's Vasomax

Preliminary results from phase I trial of Nortran's RSD-921 reported

Meridian receives approval to market its E. coli detection kit in Japan

Monarch acquires ocular therapy from Glaxo Wellcome

Biomira notified of patent allowance for Theratope

Eisai develops agents for brain cancer

Inhibitors of IL-1beta/IL-6 production from Taisho

Daiichi reports compounds for RA, allergy and transplant rejection

Antiemetics described by Dainippon

Yamanouchi discloses Na+/H+ exchange inhibitors

New agents for atherosclerosis from Bayer

Antifibrotic agents claimed by Hoechst

Hoechst discloses agents for immune/autoimmune and other disorders

Anxiolytic/nootropic agents from Asahi

Therapeutic strategies for treating disorders of gastric emptying reported at DDW

New antidiarrheal agent reported at DDW

French scientists study role of tachykinins in colitis

MF-59 adjuvant enhances immunogenicity of HBV vaccine

New developments in chemotherapy reported at DDW

Oxis International moves IBD therapy to phase II

New medicines under development for IBD reported at DDW

Carvedilol approved by FDA for CHF

Gilead's oral influenza drug enters phase II

New immunomodulator from Orion with potential in IBD

Janssen characterizes new enterokinetic agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...